Stoke Therapeutics’ (STOK) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note published on Tuesday,Benzinga reports.

STOK has been the topic of several other research reports. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Leerink Partners began coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Trading Down 5.1 %

STOK opened at $12.32 on Tuesday. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58. The business’s 50-day moving average price is $12.48 and its 200-day moving average price is $13.67. The company has a market cap of $652.59 million, a P/E ratio of -5.87 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities research analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This trade represents a 17.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. The trade was a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,000,349 shares of company stock valued at $28,031,296 over the last ninety days. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its holdings in Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC grew its stake in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after acquiring an additional 76,661 shares in the last quarter. Jane Street Group LLC grew its stake in Stoke Therapeutics by 338.2% during the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after acquiring an additional 255,028 shares in the last quarter. State Street Corp increased its holdings in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares during the last quarter. Finally, RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.